Together, these results experimental verified the stability and reliability of the GPSGC model, which further suggested that TGFβ1 and VEGFB may be developed as potential therapeutic targets for GC patients with poor prognosis according to the GPSGC. The gene discussed is TGFB1; the disease is gastric cancer.